HERC2 and cancer: Tumours that are co-mutated in TP53 (monoallelic) and HERC2 (mono- or biallelic) showed a significantly higher number of deletions compared to tumours with LOF in either gene alone (Wilcoxon test, one-tailed p < 0.031) and cancers that are WT for both genes (p < 7.2 × 10−7) (Figure 6—figure supplement 2c).